JP2007530550A - 異脂肪血症を治療するための化合物および方法 - Google Patents

異脂肪血症を治療するための化合物および方法 Download PDF

Info

Publication number
JP2007530550A
JP2007530550A JP2007505054A JP2007505054A JP2007530550A JP 2007530550 A JP2007530550 A JP 2007530550A JP 2007505054 A JP2007505054 A JP 2007505054A JP 2007505054 A JP2007505054 A JP 2007505054A JP 2007530550 A JP2007530550 A JP 2007530550A
Authority
JP
Japan
Prior art keywords
trifluoromethyl
alkyl
ethyl
amino
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530550A5 (https=
Inventor
マイケル・グレゴリー・ベル
グオキン・カオ
アナ・マリア・エスクリバノ
マリア・カルメン・フェルナンデス
ピーター・アンブローズ・ランダー
ネイサン・ブライアン・マントロ
エバ・マリア・マルティン・デ・ラ・ナバ
アナ・イサベル・マテオ・エランス
ダニエル・レイ・メイヒュー
ワン・シャオドン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2007530550A publication Critical patent/JP2007530550A/ja
Publication of JP2007530550A5 publication Critical patent/JP2007530550A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
JP2007505054A 2004-03-26 2005-03-17 異脂肪血症を治療するための化合物および方法 Pending JP2007530550A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22
PCT/US2005/009301 WO2005097806A1 (en) 2004-03-26 2005-03-17 Compounds and methods for treating dyslipidemia

Publications (2)

Publication Number Publication Date
JP2007530550A true JP2007530550A (ja) 2007-11-01
JP2007530550A5 JP2007530550A5 (https=) 2008-04-24

Family

ID=34963426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505054A Pending JP2007530550A (ja) 2004-03-26 2005-03-17 異脂肪血症を治療するための化合物および方法

Country Status (21)

Country Link
US (2) US7470705B2 (https=)
EP (2) EP1735320B1 (https=)
JP (1) JP2007530550A (https=)
KR (1) KR20070007112A (https=)
AT (2) ATE433984T1 (https=)
AU (1) AU2005230915A1 (https=)
BR (1) BRPI0508966A (https=)
CA (1) CA2557010A1 (https=)
CY (1) CY1110398T1 (https=)
DE (2) DE602005008416D1 (https=)
DK (1) DK1732933T3 (https=)
EA (1) EA200601785A1 (https=)
EC (1) ECSP066886A (https=)
ES (2) ES2326326T3 (https=)
IL (1) IL177962A0 (https=)
MA (1) MA28550B1 (https=)
NO (1) NO20064763L (https=)
PL (1) PL1732933T3 (https=)
PT (1) PT1732933E (https=)
SI (1) SI1732933T1 (https=)
WO (2) WO2005097805A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) * 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
AU2005267436A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
EP2231601B1 (en) * 2007-12-12 2014-06-18 Amgen Inc. Glycine transporter-1 inhibitors
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
WO2010130773A2 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
BR112012021448A2 (pt) * 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
LT2566505T (lt) 2010-05-06 2020-02-10 Alphacore Pharma Llc Cholesterilo esterio tiekimas į steroidogeninius audinius
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
ES2683350T3 (es) 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
US20140303198A1 (en) 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095764A (ja) * 1998-09-17 2000-04-04 Pfizer Prod Inc 環化4―カルボキシアミノ―2―メチル―1,2,3,4―テトラヒドロキノリン
JP2002526477A (ja) * 1998-09-17 2002-08-20 ファイザー・プロダクツ・インク Cetp阻害剤としての4−カルボキシアミノ−2−メチル−1,2,3,4−テトラヒドロキノリン類
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのpgd2レセプタアンタゴニスト
JP2007508301A (ja) * 2003-10-08 2007-04-05 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) * 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
JP2001511813A (ja) * 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crfレセプターアンタゴニストおよびそれらに関連する方法
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Fo−5637a物質及びb物質並びにそれらの製造法
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
EP1466904A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical BIARYL CONNECTION AND ITS USE
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
BR0306208A (pt) * 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
WO2005097805A1 (en) * 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095764A (ja) * 1998-09-17 2000-04-04 Pfizer Prod Inc 環化4―カルボキシアミノ―2―メチル―1,2,3,4―テトラヒドロキノリン
JP2002526477A (ja) * 1998-09-17 2002-08-20 ファイザー・プロダクツ・インク Cetp阻害剤としての4−カルボキシアミノ−2−メチル−1,2,3,4−テトラヒドロキノリン類
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのpgd2レセプタアンタゴニスト
JP2007508301A (ja) * 2003-10-08 2007-04-05 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法

Also Published As

Publication number Publication date
DK1732933T3 (da) 2008-10-27
PL1732933T3 (pl) 2008-12-31
ES2326326T3 (es) 2009-10-07
BRPI0508966A (pt) 2007-08-21
CY1110398T1 (el) 2015-04-29
DE602005008416D1 (de) 2008-09-04
WO2005097806A1 (en) 2005-10-20
WO2005097805A1 (en) 2005-10-20
AU2005230915A1 (en) 2005-10-20
US20070173526A1 (en) 2007-07-26
ECSP066886A (es) 2006-11-24
IL177962A0 (en) 2006-12-31
MA28550B1 (fr) 2007-04-03
SI1732933T1 (sl) 2008-10-31
ATE402180T1 (de) 2008-08-15
EP1732933A1 (en) 2006-12-20
PT1732933E (pt) 2008-10-20
US7470705B2 (en) 2008-12-30
US20070208003A1 (en) 2007-09-06
EP1735320B1 (en) 2009-06-17
ES2308477T3 (es) 2008-12-01
EP1735320A1 (en) 2006-12-27
EP1732933B1 (en) 2008-07-23
KR20070007112A (ko) 2007-01-12
CA2557010A1 (en) 2005-10-20
DE602005014955D1 (de) 2009-07-30
EA200601785A1 (ru) 2007-02-27
ATE433984T1 (de) 2009-07-15
NO20064763L (no) 2006-11-22

Similar Documents

Publication Publication Date Title
JP2007530550A (ja) 異脂肪血症を治療するための化合物および方法
JP2008504266A (ja) 異脂肪血症を治療するための化合物及び方法
CN105682656B (zh) 调节法尼醇x受体的组合物和方法
JP5586632B2 (ja) 5員の複素環式化合物のアザスピラニル−アルキルカルバメートの誘導体、この調製およびこの治療的使用
TW202003466A (zh) 人類整合素α4β7拮抗劑
KR102791742B1 (ko) (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의 합성을 위한 공정
KR20000075814A (ko) 3-아릴-4(3에이치)-퀴나졸리논의 회전장애이성질체 및 에이엠피에이-수용체 길항물질로서 그의 용도
JP7821835B2 (ja) ピペリジニルノシセプチン受容体化合物
CN101679272B (zh) 作为腺苷a3受体配体的三唑并[1,5-a]喹啉类
DK2599774T3 (en) DEHYDRATED pyridine AS CB2 cannabinoid receptor ligands
JP2001512727A (ja) 5ht−1受容体のリガンドとしてのニ環式化合物
US20070185079A1 (en) Therapeutic agents I
JPH08511277A (ja) n−アリール脂肪族−n−アルキルで機能化された新規なアミド、これらを製造する方法及びこれらが存在する薬学的組成物
JP2003231633A (ja) 医薬組成物
CA2317515A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
JP7449300B2 (ja) ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
JP2002542247A (ja) モルフィノイド化合物
CN1938320A (zh) 用于治疗异常脂肪血症的化合物和方法
CN109280028B (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用
WO2026075117A1 (en) Bridged bicyclic compounds
CN1972927A (zh) 用于治疗血脂障碍的化合物和方法
MXPA06011047A (en) Compounds and methods for treating dyslipidemia
CZ9902994A3 (cs) Aťropoisomery 3-aryl-4(3H)-chinazolinonů a jejich použití jako antagonizujících činidel receptoru AMPA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809